CAS: 98298-66-9; 1-Chloroethyl Isopropyl Carbonate

相似化合物

50594-97-3 80196-03-8 35180-01-9

上下游产品

CAS号50893-53-3 1-氯乙基氯甲酸酯 | CAS号67-63-0 异丙醇 | CAS号84089-73-6 1-碘乙基异丙基碳酸酯 | CAS号87239-81-4 头孢泊肟酯

1-氯乙基氯甲酸酯 反应生成 1-氯乙基异丙基碳酸酯
参考文献:Antifibrinolytically Active Derivatives Of Tranexamic Acid
标题:Antifibrinolytically Active Derivatives Of Tranexamic Acid
摘要:化合物的新型抗纤溶活性化合物的结构式为##str1##及其治疗上可接受的盐,其中r.Sup.1选自以下组:(A)含有1-4个碳原子的烷基基团,(B)含有1-4个碳原子的烷氧基团,##str2##r.Sup.2选自以下组:(A)H,(B)含有1-4个碳原子的烷基基团,(C)--Coor.Sup.3,其中r.Sup.3是含有1-4个碳原子的烷基基团,(D)--Conr.Sup.4 R.Sup.5,其中r.Sup.4和r.Sup.5是相同或不同的含有1-3个碳原子的烷基基团;或其中r.Sup.1和r.Sup.2共同表示如下基团##str3##

专利信息

专利号:US-5202454-A
优先权日:1986-07-11
标 题 :Process for the manufacture of 1-bromoalkyl hydrocarbyl carbonates
发明人：WOODEN GARY; SENNYEY GERARD; SENET JEAN-PIERRE
权利人:POUDRES & EXPLOSIFS STE NALE
摘要:The invention relates to a new process for the preparation of 1-bromoalkyl hydrocarbyl carbonates. The carbonates according to the invention are prepared by reacting an alpha-chlorinated carbonate of formula with an anhydrous brominated compound of formula ZBr in which Z represents hydrogen, the group (CH3)3-Si-, the group or bromine if R2 is other than an aromatic radical, in the presence of a catalyst chosen from the group consisting of heteroaromatic amines, quaternary ammonium or phosphonium halides, hexasubstituted guanidinium halides, alkaline earth metal halides or alkali metal halides in combination with a complexing agent for their cation. The carbonates according to the invention find their preferential applications as blocking agents for some antibiotics or as agents for the synthesis of phosphorus-containing carbonates which can be used as insecticides.

专利号:US-9359376-B2
优先权日:2011-04-08
标题:Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
发明人：DUGAR SUNDEEP; MAHAJAN DINESH; HOLLINGER FRANK PETER
权利人:DUGAR SUNDEEP; MAHAJAN DINESH; HOLLINGER FRANK PETER; SPHAERA PHARMA PTE LTD
摘要:The present invention relates to the synthesis and application of novel chiral/achiral substituted methyl formyl reagents to modify pharmaceutical agents and/or biologically active substances to modify the physicochemical, biological and/or pharmacokinetic properties of the resulting compounds from the unmodified original agent.